July 26, 2022 - ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series
Image For Activity Cover
No future session
Expires on Aug 26, 2022
Credit Offered
1 CME (AMA) Credit
1 CME (Other) Credit
1 Certificate of Participation Credit

First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, log in before proceeding.

For technical support, please send an email to: education@acmg.net  or call 301-718-9603.

Or click on the "Help"  icon on the left-hand side of your screen for more information.

ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series

Tuesday, July 26, 2022

11:00am-12:00pm ET



Course Description

In this session, Dr. Park will be discussing several cases brought to our Vanderbilt-Ingram Cancer Center Hereditary and Oncologic Personalized Evaluation (VICC HOPE) Molecular Tumor Board to highlight how tumor/germline next-generation sequencing (NGS), along with liquid biopsies using circulating tumor DNA (ctDNA), can result in actionable findings for patients with cancer. These cases will emphasize differences in germline findings that may or may not affect clinical decision making, as well as highlight newer technologies of RNA NGS for both tumor and germline testing, that can also lead to clinical utility.


Target Audience

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.


Presentations followed by live Q&A. 

Learning Objectives

At the conclusion of this session, participants should be able to:

1. Describe the difference between somatic testing with germline filtering and true germline testing

2. Demonstrate the application of RNA for tumor testing and germline testing

3. Discuss the importance of molecular tumor boards for correct interpretation of results for on label and off label use of cancer therapies


Beth Pitel, M.S., CG(ASCP) CM

Clinical Variant Scientist, Assistant Professor in Division of Laboratory Genetics and Genomics

Mayo Clinic, Rochester, MN


Ben Ho Park, MD, PhD

Cornelius Abernathy Craig Chair

Professor of Medicine Vanderbilt University Medical Center Director, Vanderbilt-Ingram Cancer Center 


Dr. Park attended The University of Chicago for his A.B. degree, followed by dual training at The University of Pennsylvania School of Medicine where he received both his M.D. and Ph.D. degrees. Dr. Park then trained in Internal Medicine and Hematology/Oncology at The University of Pennsylvania prior to completing a post-doctoral fellowship in the laboratory of Dr. Bert Vogelstein at Johns Hopkins. Dr. Park then joined the faculty in the Breast Cancer Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and was Professor of Oncology, Associate Director of Education and Research Training and Associate Dean of Postdoctoral Affairs for the School of Medicine prior to joining Vanderbilt University Medical Center in 2018. He is currently the Cornelius Abernathy Craig Chair, Professor of Medicine and Director of the Vanderbilt-Ingram Cancer Center. His research program involves identifying and validating genetic targets for breast cancer therapy and diagnostics. In particular, Dr. Park has pioneered the use of “liquid biopsies” to help guide future management of breast cancer therapies. He has also led the formation and implementation of molecular tumor boards at Hopkins and other institutions, and more recently at the Vanderbilt-Ingram Cancer Center.

Planning Commitee:

Beth Pitel, MS, CG(ASCP)
Gordana Raca, MD, PhD, FACMG
Manuela Benary, PhD
Jason Saliba, PhD
Jane Radford, MHA, CHCP  

CME Educational Credits:


The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

The American College of Medical Genetics and Genomics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Claiming your Educational Credits

Complete the activity and carefully complete the evaluation form. The deadline to claim educational credits is within 30 days from the date of the activity. Educational credit requests after this date will not be accepted.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


ACMG Education Policies

Please review the policies below regarding the ACMG Education program